Vaccinex (VCNX) Competitors $3.71 +0.45 (+13.80%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends VCNX vs. CPIX, CLDI, EQ, LPCN, BTAI, ATHA, LSTA, GOVX, LSB, and XCURShould you be buying Vaccinex stock or one of its competitors? The main competitors of Vaccinex include Cumberland Pharmaceuticals (CPIX), Calidi Biotherapeutics (CLDI), Equillium (EQ), Lipocine (LPCN), BioXcel Therapeutics (BTAI), Athira Pharma (ATHA), Lisata Therapeutics (LSTA), GeoVax Labs (GOVX), Lakeshore Biopharma (LSB), and Exicure (XCUR). These companies are all part of the "medical" sector. Vaccinex vs. Cumberland Pharmaceuticals Calidi Biotherapeutics Equillium Lipocine BioXcel Therapeutics Athira Pharma Lisata Therapeutics GeoVax Labs Lakeshore Biopharma Exicure Vaccinex (NASDAQ:VCNX) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, community ranking, dividends and analyst recommendations. Is VCNX or CPIX more profitable? Vaccinex has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -29.54%. Vaccinex's return on equity of 0.00% beat Cumberland Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets VaccinexN/A N/A -383.58% Cumberland Pharmaceuticals -29.54%-9.50%-3.19% Does the media refer more to VCNX or CPIX? In the previous week, Cumberland Pharmaceuticals had 2 more articles in the media than Vaccinex. MarketBeat recorded 4 mentions for Cumberland Pharmaceuticals and 2 mentions for Vaccinex. Vaccinex's average media sentiment score of 0.67 beat Cumberland Pharmaceuticals' score of -0.04 indicating that Vaccinex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaccinex 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cumberland Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Does the MarketBeat Community believe in VCNX or CPIX? Cumberland Pharmaceuticals received 64 more outperform votes than Vaccinex when rated by MarketBeat users. However, 60.00% of users gave Vaccinex an outperform vote while only 42.60% of users gave Cumberland Pharmaceuticals an outperform vote. CompanyUnderperformOutperformVaccinexOutperform Votes12360.00% Underperform Votes8240.00% Cumberland PharmaceuticalsOutperform Votes18742.60% Underperform Votes25257.40% Do institutionals & insiders have more ownership in VCNX or CPIX? 50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by insiders. Comparatively, 43.3% of Cumberland Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher valuation and earnings, VCNX or CPIX? Cumberland Pharmaceuticals has higher revenue and earnings than Vaccinex. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaccinex$570K11.02-$20.25M-$48.27-0.08Cumberland Pharmaceuticals$39.55M0.39-$6.28M-$0.77-1.43 Which has more risk and volatility, VCNX or CPIX? Vaccinex has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. SummaryVaccinex beats Cumberland Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Ad Crypto 101 Media“Sleeping Giant” Crypto Set to Explode…What if I told you there's a crypto that could make Bitcoin look like small change? We're looking at potential returns that could rewrite your financial future. Click here to discover our #1 crypto pick before it's too late Get Vaccinex News Delivered to You Automatically Sign up to receive the latest news and ratings for VCNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCNX vs. The Competition Export to ExcelMetricVaccinexPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.28M$6.42B$4.99B$8.72BDividend YieldN/A8.11%5.18%4.07%P/E Ratio-0.0810.06131.8117.48Price / Sales11.02318.981,206.0088.42Price / CashN/A22.1633.2732.46Price / Book-1.405.454.654.64Net Income-$20.25M$152.96M$117.88M$224.75M7 Day Performance5.22%-4.50%-2.58%-2.40%1 Month Performance43.48%-8.85%-4.16%-0.32%1 Year Performance-70.87%28.65%29.52%24.05% Vaccinex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCNXVaccinex0.6319 of 5 stars$3.71+13.8%N/A-73.8%$6.42M$570,000.00-0.0840CPIXCumberland Pharmaceuticals0.7451 of 5 stars$1.12+0.9%N/A-33.5%$15.73M$39.55M-1.4480Analyst ForecastCLDICalidi Biotherapeutics2.8078 of 5 stars$2.29-4.6%$16.67+627.8%N/A$25.44M$50,000.000.0041High Trading VolumeEQEquillium3.2294 of 5 stars$0.72+2.9%$5.00+596.3%+40.0%$25.44M$36.08M-5.0040Analyst RevisionLPCNLipocine2.0961 of 5 stars$4.71-1.1%$10.00+112.3%+71.8%$25.20M$500,000.00-6.2010BTAIBioXcel Therapeutics4.5194 of 5 stars$0.59-1.7%$5.00+750.3%-85.5%$25.14M$1.38M-0.2890Gap DownATHAAthira Pharma2.8517 of 5 stars$0.64-1.5%$13.83+2,053.7%-61.6%$24.84MN/A-0.2340Gap DownLSTALisata Therapeutics3.3326 of 5 stars$2.94+6.9%$15.00+410.2%+19.0%$24.68MN/A-1.1230News CoverageHigh Trading VolumeGOVXGeoVax Labs3.1662 of 5 stars$2.61-10.3%$13.25+407.7%-64.1%$24.64M$80,000.000.0017Gap DownLSBLakeshore Biopharma0.3492 of 5 stars$2.62+5.2%N/AN/A$24.38M$573.42M0.00773XCURExicure1.8445 of 5 stars$11.19+92.3%N/A+886.4%$24.28M$28.83M-3.8950News CoverageGap UpTrading HaltedHigh Trading Volume Related Companies and Tools Related Companies CPIX Competitors CLDI Competitors EQ Competitors LPCN Competitors BTAI Competitors ATHA Competitors LSTA Competitors GOVX Competitors LSB Competitors XCUR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VCNX) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Abandons USDExperts suggest we're on the brink of a major economic shift. Gold's value could soar when Trump brings bac...True Gold Republic | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredTech funds are hemorrhaging cash: Sell this stock nowSomething very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThe smart-money is buying this US$1 lithium stockLithium is getting white-hot once again! And that means well-timed investors who position now in the best n...Resource Stock Digest | SponsoredA huge crack is forming in the US economyFormer Trump Advisor Warning: “An Economic Rupture Is Coming” The legendary financier Brad Thomas served on...Wide Moat Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccinex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccinex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
